EPRX

Company Overview — What Does EUPRAXIA PHARMACEUTICALS INC. Do?

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada. EUPRAXIA PHARMACEUTICALS INC. (EPRX) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO James A. Helliwell and employs approximately 29 people, headquartered in VICTORIA, British Columbia. With a market capitalization of $451M, EPRX is one of the notable companies in the Healthcare sector.

EUPRAXIA PHARMACEUTICALS INC. (EPRX) Stock Rating — Reduce (April 2026)

As of April 2026, EUPRAXIA PHARMACEUTICALS INC. receives a Reduce rating with a composite score of 40.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.EPRX ranks #2,668 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, EUPRAXIA PHARMACEUTICALS INC. ranks #356 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

EPRX Stock Price and 52-Week Range

EUPRAXIA PHARMACEUTICALS INC. (EPRX) currently trades at $6.86. The stock lost $0.22 (3.1%) in the most recent trading session. The 52-week high for EPRX is $9.32, which means the stock is currently trading -26.4% from its annual peak. The 52-week low is $2.68, putting the stock 156.0% above its annual trough. Recent trading volume was 64K shares, suggesting relatively thin trading activity.

Is EPRX Overvalued or Undervalued? — Valuation Analysis

EUPRAXIA PHARMACEUTICALS INC. (EPRX) carries a value factor score of 29/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 12.46x, versus the sector average of 2.75x.

At current multiples, EUPRAXIA PHARMACEUTICALS INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

EUPRAXIA PHARMACEUTICALS INC. Profitability — ROE, Margins, and Quality Score

EUPRAXIA PHARMACEUTICALS INC. (EPRX) earns a quality factor score of 27/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -308.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -294.7% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

EPRX Debt, Balance Sheet, and Financial Health

EUPRAXIA PHARMACEUTICALS INC. has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $0. Cash and equivalents stand at $33M.

EPRX has a beta of 0.97, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for EUPRAXIA PHARMACEUTICALS INC. is 46/100, reflecting average volatility within the normal range for its sector.

EUPRAXIA PHARMACEUTICALS INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, EUPRAXIA PHARMACEUTICALS INC. reported revenue of $0 and earnings per share (EPS) of $-0.76. Net income for the quarter was $-26M. Operating income came in at $-27M.

In FY 2024, EUPRAXIA PHARMACEUTICALS INC. reported revenue of $0 and earnings per share (EPS) of $-0.76. Net income for the quarter was $-26M. Operating income came in at $-27M.

In FY 2023, EUPRAXIA PHARMACEUTICALS INC. reported revenue of $0 and earnings per share (EPS) of $-1.17. Net income for the quarter was $-29M. Operating income came in at $-28M.

EPRX Dividend Yield and Income Analysis

EUPRAXIA PHARMACEUTICALS INC. (EPRX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

EPRX Momentum and Technical Analysis Profile

EUPRAXIA PHARMACEUTICALS INC. (EPRX) has a momentum factor score of 63/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 18/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 61/100 reflects moderate short selling activity.

EPRX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, EUPRAXIA PHARMACEUTICALS INC. (EPRX) ranks #356 out of 838 stocks based on the Blank Capital composite score. This places EPRX in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing EPRX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full EPRX vs S&P 500 (SPY) comparison to assess how EUPRAXIA PHARMACEUTICALS INC. stacks up against the broader market across all factor dimensions.

EPRX Next Earnings Date

No upcoming earnings date has been announced for EUPRAXIA PHARMACEUTICALS INC. (EPRX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy EPRX? — Investment Thesis Summary

The quantitative profile for EUPRAXIA PHARMACEUTICALS INC. suggests caution. The quality score of 27/100 flags below-average profitability. The value score of 29/100 indicates premium valuation. Price momentum is positive at 63/100, suggesting the trend favors buyers.

In summary, EUPRAXIA PHARMACEUTICALS INC. (EPRX) earns a Reduce rating with a composite score of 40.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on EPRX stock.

Related Resources for EPRX Investors

Explore more research and tools: EPRX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare EPRX head-to-head with peers: EPRX vs AZN, EPRX vs SLGL, EPRX vs VMD.